CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Advances in Coronary No-Reflow Phenomenon-a Contemporary Review

Review Article2017 Jun 6;69(22):2759-2768.

JOURNAL:J Am Coll Cardiol. Article Link

LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation

Pothineni NVK, Karathanasis SK, Mehta JL et al. Keywords: LOX-1 blockers; coronary artery disease; endothelial cells; low-density lipoprotein; myocardial infarction; reactive oxygen species

ABSTRACT


Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.